Brain Tumours

EGFR inhibitors show efficacy in vitro but are ineffective in patients

Erlotinib

TMZ

Randomised phase II study in recurrent GBM: PFS-6 Erlotinib 11% TMZ 24%

Van den Bent et. al., J Clin Oncol, 27(8); 2009

Phase II study of erlotinib with radiotherapy and temozolomide in newly diagnosed GBM: • No improvement in outcome compared to historical controls • Worse toxicity

Perreboormtet. al., J Neurooncol, 2010